The Open Longevity project
Anastasia Egorova
Open Longevity Project
Underfunding in life extension is a well-known fact. We do face many field-specific problems when it comes to raising money for research. On the other hand, there’s an urge to contribute within non-scientific but yet aware community. Open Longevity organization, reading a lot of lectures and doing all kinds of popularization of the fight against aging, is always facing the same two questions: how can I help, not being a scientist? and what should I do with my health now? So our current project—”Clinical trials of anti-aging therapies at the expense of patients”—might be the answer. And we are all patients when it comes to aging. It is a way to contribute to clinical trials, as a subject, and as a sponsor. It provides patients with current, promising at the moment, therapies under of supervision of like-minded MDs. It creates an affordable instrument for scientists. Not to mention, giving a patients’ organization the role of a sponsor in research, we give the community the results of a study, protecting them of unaffordability of future anti-aging therapies — a common concern in the industry.
Open Longevity Project
Underfunding in life extension is a well-known fact. We do face many field-specific problems when it comes to raising money for research. On the other hand, there’s an urge to contribute within non-scientific but yet aware community. Open Longevity organization, reading a lot of lectures and doing all kinds of popularization of the fight against aging, is always facing the same two questions: how can I help, not being a scientist? and what should I do with my health now? So our current project—”Clinical trials of anti-aging therapies at the expense of patients”—might be the answer. And we are all patients when it comes to aging. It is a way to contribute to clinical trials, as a subject, and as a sponsor. It provides patients with current, promising at the moment, therapies under of supervision of like-minded MDs. It creates an affordable instrument for scientists. Not to mention, giving a patients’ organization the role of a sponsor in research, we give the community the results of a study, protecting them of unaffordability of future anti-aging therapies — a common concern in the industry.
